Navigation Links
Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
Date:4/22/2009

SEATTLE, April 22 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today presentation of preclinical data regarding its SCORPION(TM) multispecific therapeutic technology at the 100th Annual Meeting of the American Association of Cancer Research (AACR) in Denver. The data presented demonstrated the selectivity and high potency of the bispecific CD79BxDR SCORPION molecule, its differentiation from monospecific approaches, and its potential as a therapeutic for B-cell depletion, particularly in diseases refractory to CD20-targeted therapies.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

CD79BxDR SCORPION molecule: a single-chain, bispecific immunotherapeutic with potent in vitro activity against B-cell lymphoma

B-cell depletion with agents such as Rituxan(R) has proven successful in the treatment of hematological malignancies in the clinic, but patients still relapse and become refractory. Strategies to improve efficacy of B-cell directed therapies include boosting the cytotoxicity of agents and expanding to targets beyond CD20.

The objective of this preclinical model was to evaluate Trubion's SCORPION multispecific therapeutic as a next-generation candidate for oncology. An optimal bispecific molecule was identified that demonstrated highly potent activities against B-cell lymphoma cells in vitro.

The CD79BxDR SCORPION can bind to two different targets: CD79B, a lineage-restricted component of the B-cell antigen receptor, and HLA-DR, an HLA Class II molecule. Target binding by the SCORPION molecule has an affinity similar to Trubion's Small Modular Immunopharmaceutical (SMIP(TM)) proteins or monoclonal antibodies against th
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
2. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
3. Trubion Announces Presentations at Upcoming Investor Conferences
4. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
5. Trubion Announces Presentations at Upcoming Investor Conferences
6. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
7. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
8. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
9. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
10. Trubion Announces Presentations at April/May Investor Conferences
11. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... NEW BRUNSWICK , Nueva Jersey , 22 ... Award for Biomedical Research abre hoy su llamada ... las personas cuya investigación científica ha hecho, o tiene ... de la salud humana. Las nominaciones se aceptarán hasta ...
(Date:1/22/2015)... Jan. 22. 2015  Varian Medical Systems (NYSE: VAR ... honored for its commitment to sustainability with inclusion on a ... the highest ranked healthcare equipment company among the Corporate Knights ... World Economic Forum at Davos, Switzerland . ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: UTHR ... MDT ) has submitted a pre-market approval application to ... use of Medtronic,s SynchroMed ® II implantable drug ... with United Therapeutics, Remodulin ® (treprostinil) Injection delivered ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... fields to drive iron-bearing nanoparticles to metal stents in ... payload that successfully prevents blockages in those vessels. In ... at a lower dose than conventional non-magnetic stent therapy. ... is the latest in a series of studies at ...
... ... and xenograft response prediction. MM-111 breast cancer study in combination with trastuzumab. , ... Cambridge, MA (PRWEB) April ... on MM-121 and MM-111, the two lead candidates in the company’s pipeline of five ...
... Doctors could soon be prescribing a dose of dark ... from dangerously high blood pressure in their abdomen, according ... Liver CongressTM 2010, the Annual Meeting of the European ... According to the Spanish research, eating dark chocolate ...
Cached Biology Technology:Magnetic fields drive drug-loaded nanoparticles to reduce blood vessel blockages in an animal study 2Magnetic fields drive drug-loaded nanoparticles to reduce blood vessel blockages in an animal study 3Magnetic fields drive drug-loaded nanoparticles to reduce blood vessel blockages in an animal study 4Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR) 2Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR) 3Study shows potential benefit of dark chocolate for liver disease patients 2
(Date:1/22/2015)... /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry news, ... website design. "When we launched FindBiometrics 12 years ... O,Neill , founder and CEO of FindBiometrics. "Now it,s maturing ... the key players on a very broad scale.  We are ...
(Date:1/22/2015)... 2015  BellBrook Labs, a leader in high throughput ... of a TR-FRET (time resolved Forster resonance energy ... a high throughput screening assay for glycosyltransferases and ... for sensitive detection of hundreds of human and ...
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... technology and tech stocks, releases video from the CES 2015 ... security consultant Apollo Robbins . Apollo shows ... Wocket™ biometric smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... of cancer, including stomach, liver and colon, are far more ... that differences in lifestyle, such as diet and smoking, may ... differences are rooted in basic biological differences between men and ... MIT shows that treating male mice with estrogen dramatically lowers ...
... giant seaweeds, are spreading fast, with harmful effects on ... the Mediterranean seabed. Some native species, such as sea ... invasion, but only during its early stages, or when ... carried out a study to look at the ability ...
... salmon were to escape from captivity they could succeed ... Canadian researchers have found. Their research, published in ... GM salmon as they are considered for commercial farming. ... long been of interest to the aquaculture industry and ...
Cached Biology News:Study explains why men are at higher risk for stomach cancer 2Study explains why men are at higher risk for stomach cancer 3Sea urchins cannot control invasive seaweeds 2First study into GM Atlantic salmon mating reveals danger of escape to wild gene pool 2
... anti-phospho-FAK (Ser843) ... acid region encompassing the human, mouse, ... Accession Number: NM_153831 ... Routinely evaluated by immunoblot. ...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Phospho-YAP (Ser127) Antibody Ship: Hot Store: -20 C...
Biology Products: